Theo Outlook
Regeneron Pharmaceuticals (REGN) presents a bullish investment thesis, trading at a forward P/E of 17.0 with trailing EPS of $41.46 and a market cap of $78B. TTM revenue stands at $14.3B with 2.5% quarterly growth YoY, supported by a low beta of 0.40 for reduced volatility. The stock's current price of $737.71 is below the analyst target of $873, implying significant upside potential amid strong fundamentals.
Key catalysts include a history of earnings beats, such as an 8.7% surprise in Q4 2025 (EPS $11.44 vs. $10.52 est.) and robust product portfolio with Eylea and Dupixent royalties driving momentum. Upcoming Q1 2026 earnings on April 29 carry an EPS estimate of $5.96, while ongoing pipeline advancements in oncology and immunology position REGN for market expansion. Analyst ratings favor buys (19 total) reinforcing growth drivers.
Risks encompass biotech-specific challenges like clinical trial setbacks, patent expirations for key drugs, and regulatory scrutiny from the FDA, compounded by a recent -2.6% quarterly earnings growth. Competitive pressures in monoclonal antibodies from rivals like Roche add headwinds. Mitigations include REGN's $4.2B EBITDA for R&D funding, diversified revenue streams, and low beta to weather macro downturns.
Analysis generated by HeyTheo AI based on SEC filings, earnings transcripts, and market data.